Matricelf (TASE: MTLF) Enters Strategic Collaboration with Sheba Medical Center to Advance First in Human Clinical Program in Spinal Cord Injury

Core Insights - Matricelf Ltd. has entered a strategic collaboration with Sheba Medical Center to advance its first human clinical trial for spinal cord injury treatments [1][2] - This partnership marks a significant transition for Matricelf from preclinical development to clinical stage, aiming for human proof of concept [2][4] Collaboration Details - The collaboration will involve GMP compliant manufacturing of autologous neural tissue implants at Sheba's Advanced Biotherapy Center [2][3] - The clinical trial will leverage Sheba's integrated environment, combining advanced manufacturing, surgical expertise, and rehabilitation capabilities [3][4] Operational Efficiency - Centralizing manufacturing and clinical execution at a leading institution is expected to streamline operations, reduce execution risk, and accelerate clinical timelines [4] - This approach is designed to establish a scalable model for future expansion [4] Preclinical Progress - The milestone builds on positive preliminary safety data from preclinical studies, which demonstrated the safety profile of Matricelf's engineered neural tissue platform in animal models [5] - Additional data is anticipated to support regulatory progression into human clinical studies [5] Leadership Statements - Dr. Alon Sinai, Founder and President of Matricelf, emphasized that advancing into clinical development is a defining milestone for the company [6] - CEO Gil Hakim highlighted that the collaboration enhances efficiency and supports de-risking of early-stage clinical development [6]